Sanofi Sponsored ADR Stock

$49.84

0.14% yesterday

Nasdaq, Aug 18, 10:02 pm CET

ISIN

US80105N1054

Symbol

SNY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Sanofi Sponsored ADR Stock price

$49.84

-2.18 4.19% 5Y

Nasdaq, Closing price Mon, Aug 18 2025

+0.07 0.14%

ISIN

US80105N1054

Symbol

SNY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$119.2b

Enterprise Value

$127.3b

Net debt

$8.1b

Cash

$18.0b

Shares outstanding

1.3b

Valuation (TTM | estimate)

P/E

4.7 | 5.1

P/S

1.9 | 2.2

EV/Sales

2.0 | 2.4

EV/FCF

9.6

P/B

1.5

Dividends

DPS

$2.20

Yield 1Y | 5Y

4.4% | 4.0%

Growth 1Y | 5Y

7.8% | 5.3%

Payout 1Y | 3Y

39.4% | 32.6%

Increased

2 Years

Financials (TTM | estimate)

Revenue

$62.9b | $53.3b

EBITDA

$16.1b | $16.8b

EBIT

$14.0b | $14.2b

Net Income

$12.9b | $12.2b

Free Cash Flow

$13.3b

Growth (TTM | estimate)

Revenue

34.5% | 2.9%

EBITDA

38.8% | 36.5%

EBIT

46.1% | 39.0%

Net Income

160.9% | 87.7%

Free Cash Flow

167.4%

Financial Health

Equity Ratio

58.4%

Return on Equity

7.2%

ROCE

12.4%

ROIC

10.8%

Debt/Equity

0.3

EPS

$10.5

FCF per Share

$10.6

Short interest

0.2%

Employees

83k

Rev per Employee

$630.0k

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

??

29 Analysts have issued a Sanofi Sponsored ADR forecast:

20x Buy

69%

9x Hold

31%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy

69%

Hold

31%

Analyst Estimates with Stock Price Targets

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	62,896 62,896	34% 34% 100%
- Direct Costs	17,705 17,705	24% 24% 28%
Gross Profit	45,191 45,191	39% 39% 72%
- Selling and Administrative Expenses	12,467 12,467	32% 32% 20%
- Research and Development Expense	11,115 11,115	43% 43% 18%
EBITDA	16,143 16,143	39% 39% 26%
- Depreciation and Amortization	2,182 2,182	5% 5% 3%
EBIT (Operating Income) EBIT	13,962 13,962	46% 46% 22%
Net Profit	12,873 12,873	161% 161% 20%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sanofi Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted ...

Negative

Reuters

●

7 days ago

Sanofi stops supply of high cholesterol drug to China due to limited availability

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability.

Positive

Seeking Alpha

●

11 days ago

Sanofi: Playing To Win

Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongside a robust late-stage pipeline, underpin future revenue potential. Risks include heavy Dupixent reliance, looming patent expirations, US policy uncertainty, and ongoing legal disputes with Regene...

More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office	France
CEO	Paul Hudson
Employees	82,878
Founded	1994
Website	www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now